About Nyxoah SA

Company Description

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).

Nyxoah’s lead solution platform is based on the Genio® system, a CE-Mark validated, patient-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the world’s most common sleep disordered breathing condition that is associated with increased mortality risk* and comorbidities including cardiovascular diseases, depression and stroke.

Year founded

2009

Served area

Worldwide

Headquarters

Rue Edouard Belin 12, 1435 Mont-Saint-Guibert – Belgium

Shareholder information

Shares outstanding

25,846,279

IPO

Sept. 18, 2020

Stock exchange(s)

Euronext Brussels

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.